A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910